Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 25 June 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Demand for fertility treatment-related products remained firm in Japan and overseas, and sales increased in overseas markets, mainly in Europe and India. Gross profit increased due to higher sales and changes in the product mix. The company increased investment in sales activities and certification costs while controlling other expenses. Foreign exchange gains also increased as the yen weakened during the fiscal year.
| Item | Details |
|---|---|
| Net Sales | ¥10,602 million → ¥10,947 million（+3.3%） |
| Operating profit | ¥5,374 million → ¥5,858 million（+9.0%） |
| Ordinary income | ¥5,267 million → ¥5,903 million（+12.1%） |
| Profit attributable to owners of the parent | ¥3,498 million → ¥3,895 million（+11.3%） |
| Net income per share | ¥87.46 → ¥97.38（+11.3%） |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 25 June 2025 |
| Previous-period results | Net Sales ¥10,302 million / Operating profit ¥5,782 million / Ordinary income ¥5,767 million / Profit attributable to owners of the parent ¥3,788 million / Net income per share ¥94.72 / Fiscal Period Covered Fiscal year ended March 2025 |
| Reason for the revision | Demand for fertility treatment-related products remained firm in Japan and overseas, and sales increased in overseas markets, mainly in Europe and India. Gross profit increased due to higher sales and changes in the product mix. The company increased investment in sales activities and certification costs while controlling other expenses. Foreign exchange gains also increased as the yen weakened during the fiscal year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Demand for fertility treatment-related products remained firm both in Japan and overseas, and overseas sales increased, mainly in Europe and India. In addition, gross profit increased due to changes in the product mix, while investment in sales activities and certification costs increased and other expenses were controlled. Foreign exchange gains also increased as the yen weakened during the fiscal year.